Final answer:
The EMPA-REG OUTCOME trial demonstrated that empagliflozin significantly reduced major adverse cardiovascular events, hospitalization for heart failure, and cardiovascular mortality in type 2 diabetes patients, indicating safety and cardiovascular benefits.
Step-by-step explanation:
The EMPA-REG OUTCOME trial was a significant study that evaluated the cardiovascular safety of empagliflozin, a medication used to treat type 2 diabetes. It particularly looked at the safety results concerning cardiovascular events. The trial found that empagliflozin led to a significant reduction in the risk of major adverse cardiovascular events, including hospitalization for heart failure and death from cardiovascular causes. In summary, the safety results from the EMPA-REG OUTCOME trial were positive, demonstrating that empagliflozin is not only safe from a cardiovascular standpoint but also provides cardiovascular benefits to patients with type 2 diabetes.